M Bio Technology
Research and development company focused on diagnosis, treatment and prevention of mycoplasma infectious diseases. Core capabilities include discovery and chemical synthesis of mycoplasma-specific glycolipid antigens, development of a high-uniformity serological assay, vaccine platform development using synthetic antigens and liposome/pseudoparticle formats, and generation of monoclonal antibodies. The organization pursues clinical collaborations, manufacturing scale-up with partners, and licensing/alliances to deploy technologies and diagnostics.
Industries
Nr. of Employees
small (1-50)
M Bio Technology
Patents
Method for producing an isolated monoclonal antibody specifically binding to a glycolipid antigen of mycoplasma pneumoniae
US-10870669-B2
View Details
Method for producing an isolated monoclonal antibody specifically binding to a glycolipid antigen of mycoplasma pneumoniae
US-10870669-B2
View DetailsProducts
Serological diagnostic assay using synthetic mycoplasma glycolipid antigen (ELISA)
An ELISA-based serological test that measures IgM, IgG and IgA against chemically synthesized mycoplasma glycolipid antigens to detect two specified mycoplasma species.
Vaccine program using synthetic glycolipid antigen (liposome/pseudoparticle)
Vaccine R&D program that uses chemically synthesized glycolipid antigens presented as liposome or pseudoparticle formulations to elicit specific immune responses; includes preclinical vaccine prototypes and partnership-seeking for development.
Monoclonal antibody development program
Program to produce monoclonal antibodies specific to mycoplasma antigens using synthetic antigen-mimicking particles and bioreactor-based production for therapeutic development.
Serological diagnostic assay using synthetic mycoplasma glycolipid antigen (ELISA)
An ELISA-based serological test that measures IgM, IgG and IgA against chemically synthesized mycoplasma glycolipid antigens to detect two specified mycoplasma species.
Vaccine program using synthetic glycolipid antigen (liposome/pseudoparticle)
Vaccine R&D program that uses chemically synthesized glycolipid antigens presented as liposome or pseudoparticle formulations to elicit specific immune responses; includes preclinical vaccine prototypes and partnership-seeking for development.
Monoclonal antibody development program
Program to produce monoclonal antibodies specific to mycoplasma antigens using synthetic antigen-mimicking particles and bioreactor-based production for therapeutic development.
Services
Negotiation and collaboration for licensing of antigen, diagnostic and vaccine technologies with pharmaceutical and manufacturing partners.
Prototype and medium-scale production support for ELISA diagnostics and liposome vaccine formulations in partnership with manufacturers, with a view to further scale-up.
Provision of the company’s serological diagnostic test through a network of designated medical institutions in Japan, including clinician-guided confirmatory testing and referral pathways.
Online diagnostic questionnaires and physician-led remote consultations, with pathways to laboratory blood testing and diagnosis.
Negotiation and collaboration for licensing of antigen, diagnostic and vaccine technologies with pharmaceutical and manufacturing partners.
Prototype and medium-scale production support for ELISA diagnostics and liposome vaccine formulations in partnership with manufacturers, with a view to further scale-up.
Provision of the company’s serological diagnostic test through a network of designated medical institutions in Japan, including clinician-guided confirmatory testing and referral pathways.
Online diagnostic questionnaires and physician-led remote consultations, with pathways to laboratory blood testing and diagnosis.
Expertise Areas
- Mycoplasma infectious disease diagnostics
- Chemical antigen synthesis
- Vaccine research and formulation
- Therapeutic monoclonal antibody development
Key Technologies
- Chemical synthesis of glycolipid antigens
- Antigen structural analysis
- ELISA serological assay (IgM/IgG/IgA)
- Liposome/pseudoparticle vaccine formulation
News & Updates
Company selection for the Deep Tech Course of JETRO's Global Startup Accelerator Program 2024.
Selected to exhibit at the Japan Healthcare Venture Summit 2024 (Pacifico Yokohama).
Article discussing potential relationships between long-term COVID-19 symptoms and mycoplasma infection.
Recipient of the New Value Creation Award at the Organization for Small & Medium Enterprises and Regional Innovation New Value Creation Exhibition 2018.
Company selection for the Deep Tech Course of JETRO's Global Startup Accelerator Program 2024.
Selected to exhibit at the Japan Healthcare Venture Summit 2024 (Pacifico Yokohama).
Article discussing potential relationships between long-term COVID-19 symptoms and mycoplasma infection.
Recipient of the New Value Creation Award at the Organization for Small & Medium Enterprises and Regional Innovation New Value Creation Exhibition 2018.